Hock BD - Search Results

1

Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.

Keating PE, Hock BD, Smith SM, Chin PKL, O'Donnell JL, Barclay ML. Keating PE, et al. Among authors: hock bd. Intern Med J. 2023 Nov;53(11):2123-2127. doi: 10.1111/imj.16264. Intern Med J. 2023. PMID: 37997271 Review.

2

Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients.

Hock BD, O'Donnell JL, Taylor K, Steinkasserer A, McKenzie JL, Rothwell AG, Summers KL. Hock BD, et al. Tissue Antigens. 2006 Jan;67(1):57-60. doi: 10.1111/j.1399-0039.2005.00524.x. Tissue Antigens. 2006. PMID: 16451202

3

CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data.

Hock BD, McKenzie JL, McArthur L, Tansley S, Taylor KG, Fernyhough LJ. Hock BD, et al. Intern Med J. 2010 Dec;40(12):842-9. doi: 10.1111/j.1445-5994.2009.02135.x. Intern Med J. 2010. PMID: 20002855

4

Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre.

Fernyhough LJ, Hock BD, Taylor J, Pearson J, Ganly P. Fernyhough LJ, et al. Among authors: hock bd. Intern Med J. 2013 Feb;43(2):130-7. doi: 10.1111/j.1445-5994.2012.02819.x. Intern Med J. 2013. PMID: 22530659

5

Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.

Hock BD, Stamp LK, Hayman MW, Keating PE, Helms ET, Barclay ML. Hock BD, et al. Ther Drug Monit. 2016 Feb;38(1):32-41. doi: 10.1097/FTD.0000000000000229. Ther Drug Monit. 2016. PMID: 26222874

6

Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients.

Hock BD, McIntosh ND, McKenzie JL, Pearson JF, Simcock JW, MacPherson SA. Hock BD, et al. Intern Med J. 2016 Dec;46(12):1414-1421. doi: 10.1111/imj.13261. Intern Med J. 2016. PMID: 27664975

7

Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.

Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M. Barclay ML, et al. Intern Med J. 2019 Apr;49(4):513-518. doi: 10.1111/imj.14064. Intern Med J. 2019. PMID: 30091273

8

Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.

Hock BD, Mulholland KS, Ganly P, McKenzie JL, Pearson JF, MacPherson SA. Hock BD, et al. Intern Med J. 2019 May;49(5):598-606. doi: 10.1111/imj.14155. Intern Med J. 2019. PMID: 30411451

9

Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.

Hock BD, McKenzie JL, Goddard L, Smith SM, McEntyre CJ, Keating PE. Hock BD, et al. Ther Drug Monit. 2018 Dec;40(6):705-715. doi: 10.1097/FTD.0000000000000553. Ther Drug Monit. 2018. PMID: 30439789

10

Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum.

Hock BD, Smith SM, McEntyre CJ, McKenzie JL, Sies C, Keating PE. Hock BD, et al. J Immunol Methods. 2019 Nov;474:112672. doi: 10.1016/j.jim.2019.112672. Epub 2019 Sep 13. J Immunol Methods. 2019. PMID: 31525368

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters